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Abstract
Background: Antiretroviral therapy (ART) adherence in preventing HIV mother-to-child transmission in association
with virological suppression and risk factors of low adherence in the Cameroon’s Option B+ programme are poorly
understood. We used a composite adherence score (CAS) to determine adherence and risk factors of poor adherence
in association with virological treatment response in HIV-positive pregnant and breastfeeding women who remained
in care at 6 and 12 months after initiating ART.
Methods: We prospectively enrolled 268 women after ART initiation between October 2013 and December 2015 from
five facilities within the Kumba health district. Adherence at 6 and 12 months were measured using a CAS comprising
of a 6-month medication refill record review, a four-item self-reported questionnaires and a 30-day visual analogue scale.
Adherence was defined as the sum scores of the three measures and classified as high, moderate and low. Measured
adherence levels were compared to virological suppression rates at month 12 and risk factors of poor adherence were
determined.
Results: At 6 and 12 months, 217 (81.0%) and 185 (69.0%) women were available for adherence evaluation. Respectively.
Of those, 128 (59.0%) and 68 (31.4%) had high or moderate adherence as per the CAS tool at month 6, and 116 (62.7%)
and 48 (24.9%) at month 12, respectively. Viral loads were assessed in 165 women at months 12, and 92.7% had viral
suppression (< 1000 copies/mL). Viral suppression was seen in 100% of women with high, 89.5% with moderate, and
52.9% with low adherence using the CAS tool. Virological treatment failure was significantly associated with low
adherence [OR 7.6, (95%CI, 1.8–30.8)]. Risk factors for low adherence were younger age [aOR 3.8, (95%CI, 1.4–10.6)],
primary as compared to higher levels of education [aOR 2.7, (95%CI, 1.4–5.2)] and employment in the informal sector
compared to unemployment [aOR 1.9, (95%CI,1.0–3.6)].
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Conclusions: During the first year of Option B+ implementation in Cameroon our novel CAS adherence tool was
feasible, and useful to discriminate ART adherence levels which correlated with viral suppression. Younger age, less
educated and informal sector employed women may need more attention for optimal adherence to reduce the risk
of virological failure.
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Background
Adherence to antiretroviral therapy (ART) for HIV infection
is essential for plasma viral load suppression. This is key to
treatment success as it reduces both morbidity and mortality
but most importantly improves the quality of life and re-
duces drug resistance development [1–3]. Non-adherence is
the most important factor that leads to viral resistance [4].
As test and treat is being adopted worldwide including Op-
tion B+ procedures for newly diagnosed HIV-positive preg-
nant and breastfeeding women, additional adherence and
retention support are needed as most of the patients initiat-
ing ART present with asymptomatic HIV infection [5, 6].
Since the introduction of Option B+ in Malawi in 2011,
ART uptake has significantly improved for this target group
but there are still concerns that women with asymptomatic
HIV infection may not be adequately retained or poorly ad-
here to treatment [7–9]. Recent studies since the introduc-
tion of Option B+ have focused on retention in care [8, 10,
11] and very little data is available assessing patients’ adher-
ence to ART. Evidence also shows that retention, which is
often used as a surrogate for adherence, may fail to account
for the pattern of clinic attendance and drug taking behav-
iour [12]. The few studies evaluating adherence to Option B
+ used a single adherence measure such as self-report or
pharmacy refill which both have been shown to overestimate
adherence [13, 14]. Overestimated adherence could result in
patient misclassification and lead to inaccurate targeting of
adherence-improving interventions or delays in addressing
adherence problems. Self-reported adherence is subjective
and its reliability drops overtime as patients get acquainted
with the assessment tool used [15]. Pharmacy refills and pill
counts on their part, though objective and not easily affected
by recall and social desirability biases, may result in ‘pill
-dumping’, thus overestimating adherence [16, 17]. Viral load
(VL) suppression data can provide additional information to
improve adherence assessment conducted using any subject-
ive measure, though it could also be affected by pre-treat-
ment HIV drug resistance [18]. To optimise the Option B+
programme and reduce the risk of treatment failure, timely
and adequate assessment of adherence in HIV-positive preg-
nant and breastfeeding women with a simple but robust tool
is critical in resource limited settings where second line
medication options are limited and third line regimens are
virtually non-existent or are still very expensive [2, 5].
Sub-optimal adherence needs to be identified and addressed
early prior to treatment failure and the development of viral
drug resistance. This is possible only if we understand the
risk factors of poor adherence and those enablers of proper
medication taking behaviour. These factors have been stud-
ied in other settings but are poorly understood in Cameroon
[19, 20]. In order to meet the UNAIDS 90–90-90 objective
by 2020 [21], treatment programmes should not only focus
on HIV testing, ART initiation and retention in care, but also
on adherence to lifelong ART which is key to reaching the
3rd 90. However, notwithstanding the importance of
near perfect adherence on viral suppression, recent
research findings are showing that newer ART regi-
mens may only require moderate adherence levels to
achieve viral suppression [22–24].
In our previous analysis of this cohort of pregnant or
breastfeeding women, we observed good uptake of HIV
testing and counselling, ART and retention in care, which
however, declined over time. We analysed treatment dis-
continuation taking into account women lost to follow up,
transferred out to other ART clinics, intentionally stopped
medication or died. Discontinuation from Option B+ was
highest at small sites with a high staff turnover [8]. Based
on those findings, we now specifically evaluated informa-
tion on women who remained in care with respect to
ART adherence in association with viral suppression using
a multiple method tool. We further investigated risk fac-
tors associated with poor adherence alongside enablers of
proper drug taking behaviour.
Methods
Study design and settings
This prospective cohort study was carried out between
October, 2013 and December 2015 at five health facil-
ities located within the Kumba Health District, South
West Region, Cameroon, which all provide integrated
maternal, neonatal, child health and prevention of
mother to child transmission (PMTCT) services. These
sites were among the ten facilities that piloted Option B
+ in the region from October, 2013. They receive well
over 90% of all pregnant women seeking antenatal care
(ANC) in the health district, and also had their staff
trained in Option B+ procedures and task shifting as
part of the pilot project. Task shifting allows midwives
and nurses to prescribe ART and follow-up the mother
baby pair [25].
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Study participants, procedures, outcomes and definitions
The study participants and procedures were previously
described [8]. For the current analysis, which focused on
adherence using a composite adherence score and viral
suppression, we included women who remained in care
at six and twelve months after ART initiation. In brief,
ART was offered as a once daily regimen with a fixed
dose combination of tenofovir, lamivudine and efavirenz
regardless of clinical or immunological status in accord-
ance with WHO and national guidelines [5, 26]. ART
follow-up cards were opened for each ART initiating cli-
ent from which information on age, date and timing of
ART initiation, previous ART history, WHO staging,
CD4 T-cell counts, level of education, profession, reli-
gious affiliation, and marital status was documented. Ad-
herence and VL information were completed on
subsequent follow-up visits when available. ART visits
were scheduled monthly in a way that provided at least
4 days buffer supply of medications. Visits were man-
aged at ANC or infant welfare clinics (IWC) post-
delivery by trained nurses or midwives. During each re-
fill visit, women received routine information and sup-
port on adherence, and every 6 months each women
underwent a comprehensive adherence assessment. Data
extraction and interviews were conducted by nurses and
midwives who were trained as study staff. VL testing
was performed 12 months after ART initiation when VL
became routine for patient monitoring using the Real
Time HIV-1 m2000™ System (Abbott Laboratories, Illi-
nois, USA). VL samples were not collected if either the
woman missed her clinic visit on the day of sample col-
lection or had multimonth refills during a previous visit.
Virological suppression was defined as any value < 1000
copies/mL on a single measurement according to WHO
and national guidelines [4, 26]. Women with low repli-
cating viraemia (40 and 999 copies/mL) were subjected
to re-enforced adherence counselling, those with sus-
pected virological treatment failure (VL ≥1000 copies/
mL) also received re-enforced adherence support and re-
peated VL testing within 3 months if adherence was
judged satisfactory. During re-enforced adherence, indi-
vidual adherence challenges were identified by psycho-
social support staffs who then worked with individual
clients until viral load retesting after adherence was
judged satisfactory.
The primary study outcome was ART adherence at six
and twelve months after Option B+ initiation using a
validated multi-method tool adapted from South Africa
[27]. We included medication refill record review (ARV
pick-up appointments) as ARVs in Cameroon are
sourced and distributed by a sole body through ap-
proved ARV treatment centres and Option B+ sites free
of charge. Adherence was assessed using a six monthly
medication refill record review, a four-item self-reported
adherence questionnaire, and a thirty days visual
analogue scale (VAS).
Medication refill records for each woman over the past
6 months were reviewed by the study staff to track the
total number of refills effected using the patient ART co-
hort register. A face-to-face interview was then adminis-
tered, prefaced by a normalizing language in order to
reduce social desirability bias [28, 29]. The interviewer
then administered the four closed ended questions for-
mulated such that the right answer was a no to reduce
the “white coat effect” [27]. The four questions used to
evaluate self-reported adherence were (i) “Do you some-
times find it difficult to remember to take your medi-
cine?”; (ii) “When you feel better, do you sometimes stop
taking your medicine?”; (iii) “Thinking back over the past
4 days, have you missed any of your doses?”; and (iv)
“Sometimes if you feel worse when you take the medicine,
do you stop taking it?” [27]. Two additional questions
were administered to probe for reasons of missing doses
and enhancers of drug taking behaviour as follows; (i)
“What causes you to miss some doses of your drug?”, and
(ii) “What helps you remember to take your drugs?”
Women were finally asked to estimate adherence on a
linear VAS, (Fig. 1), which included a score ranging from
zero (no adherence) to ten (optimal adherence) over the
last 30 days [30, 31].
Adherence was scored separately for each adherence
measure with a score on 3 indicating high, 2 moderate
and 1 low adherence (Table 1). Overall adherence was
estimated by creating a composite adherence score
(CAS), which included the sum of the scores from each
of the three measures and classified adherence as high,
moderate or low. To avoid overweighting, once adher-
ence was scored as poor on pharmacy refill the CAS was
low irrespective of the scores on the questionnaire and
the VAS.
Secondary outcomes included risk factors of poor ad-
herence, reasons for missing medications, reminders
commonly used to enhance adherence, and the correl-
ation between different adherence tools and the CAS. In
Fig. 1 Visual Analogue Scale (VAS)
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assessing the risk factors associated with poor adher-
ence, all women who had discontinued treatment at or
before 12 months after ART initiation were considered
as the worst case of adherence and were included into
the low adherence category.
Statistical analysis
Data were collected on study specific case report forms,
entered into an Excel spread sheet and corrected for in-
consistency before extraction for analysis. Descriptive
statistics were used to examine the baseline socio-demo-
graphic, laboratory and clinical characteristics of the
study participants at ART initiation. Binary logistic re-
gression was used to assess the association between ad-
herence scores by different adherence tools and viral
suppression, as well as to assess the risk factors for poor
adherence. Unadjusted odd ratios (OR) and 95% confi-
dence intervals (CI) were reported. For risk factor, vari-
ables with significant or marginal association (p < 0.100)
and those previously reported to be associated with poor
adherence were included into the multivariate analyses
reporting the adjusted odd ratios (aOR) for poor adher-
ence. An alpha level of < 0.05 was set to define signifi-
cance. Spearman correlation was used to compare the
performance of the different adherence measures with
each other and with the CAS. Data were analysed using
the IBM Statistical Package for Social Sciences (version
21, IBM SPSS Inc., Chicago IL, USA).
Results
Baseline characteristics of the study participants
Of the 268 women starting Option B+, 253 (94.4%) initi-
ated ART prior to labour/delivery and 15 (5.6%) during
breastfeeding. Patients’ baseline socio-demographic, HIV
status, clinical and laboratory characteristics are pro-
vided in Table 2. In brief, the median age at ART initi-
ation was 27 (IQR 24–31) years, a minimum of primary
level of education was attained in 263 (98.1%) and 105
(39.2%) were unemployed. At ART initiation the median
CD4+ T-cell count was 376 cells/mL, (IQR 244–544.8),
234 (87.3%) were ART naïve, whereas 4 (1.5%) had been
exposed to ARV during previous pregnancies. In
addition, 30 (11.2%) women already received Option A
during their current pregnancy and were switched to
Option B+ triple regimens.
Adherence measurements and the performance of the
different tools
After six and twelve months 217 (81.0%) and 185
(69.0%) of women were still available for adherence ana-
lysis, respectively. Adherence levels determined by CAS
for women retained in care at months 6 and 12 were
high in 128 (59.0%) and 116 (62.7%) cases, moderate in
68 (31.4%) and 48 (24.9%), and low in 21 (9.6%) and 23
(12.4%), respectively (Table 3).
Differences within adherence estimates were further
assessed by comparing correlation coefficients at each ad-
herence time-point (Table 4). All adherence measures
were correlated with each other. Significant correlation
with the CAS by Spearman correlation were seen for all
comparisons (p < 0.001), ranging from 0.36 to 0.83. How-
ever, the highest linear correlation was observed between
the VAS and CAS which remained consistent both at 6
and 12 months with a Spearman correlation of 0.83.
Adherence and virological suppression
Of the 185 women assessed for adherence at months 12,
VL was performed in 165 (90.7%) women. Of those 139
(84.2%) had undetectable VL < 40 copies/mL, 14 (8.5%)
low level replication between 40 and 999 copies/mL, and
12 (7.3%) evidence for virological treatment failure
≥1000 copies/mL. Viral suppression < 1000 copies/mL
was positively associated with high adherence as esti-
mated by CAS in 100%, with moderate adherence in
89.5% and low adherence in 52.9% (Table 5). All adher-
ence measures showed statistically significant differences
between high adherence when compared with low ad-
herence and virological suppression. In bivariate regres-
sion analysis there was a strong positive association
between virological failure and low adherence for all ad-
herence tools. Using the CAS, all clients who reported
high adherence were virologically suppressed and mod-
erate adherence showed statistically significant difference
Table 1 Interpretation of the single adherence measures and the composite adherence score (CAS)
Single adherence tool* Medication refill Had 6 refills (3) Missed 1 refill (2) Missed 2 or more refills (1)
Self-report questionnaire No to all 4 questions (3) Yes to 1 question (2) Yes to 2 or more questions (1)
VAS 90% or more (3) 80% to less than 90% (2) Less than 80% (1)
Composite adherence tool Medication refill score 3 3 3 3 3 2 3 2 2 1
Self-report questionnaire score 3 3 3 2 2 2 1 2 1 1
VAS score 3 2 1 2 1 2 1 1 1 1
CAS 9 8 7 7 6 6 5 5 4 3
Overall adherence High Moderate Low
CAS composite adherence score, VAS visual analogue scale; Single adherence scores: 3 = high adherence, 2 =moderate adherence, 1 = low adherence;
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with virological suppression when compared to low ad-
herence [OR 7.6, (95%CI, 1.8–30.8)] .
Risk factors associated with low adherence
In both bivariate and multivariate regression analyses ad-
justed for socio-demographics and other HIV and la-
boratory characteristics, low adherence was statistically
significant with younger as compared to older ages [aOR
3.8, (95%CI, 1.4–10.6)], completed primary compared to
completed secondary education and above [aOR 2.7,
(95%CI, 1.4–5.2)] and employment in the informal sec-
tor when compared to unemployment [aOR 1.9, (95%C,
1.0–3.6)] (Table 6).
Religious affiliation, marital status, initial CD4 T-cell
count at ART initiation, WHO stage and timing of ART
initiation were not associated with low adherence.
Reasons for missed medication doses and factors that
helped to remind medication taking
During adherence assessment at month 12, 121 women
gave reasons why doses were missed. Frequently cited
reasons were forgetfulness by 43 (35.5%), travel away
from home by 21 (24.0%) and lack of transport to the
clinic by 28 (23.1%) women. Side effects, stigmatization,
distracted by the baby, being away for work and being
involved in church or other social activities were less fre-
quently cited. Asking about factors that helped to re-
mind medications taking, 172 women provided one or
more responses. The most frequently cited were the use
of cell phone by 64 (37.2%) women, 63 (36.6%) indicated
that drug taking had become a routine in their life so it
Table 2 Baseline socio-demographic, clinical and laboratory
characteristics of women who started triple ART for PMTCT
Option B+ in Kumba Health District, South West Region,
Cameroon between October 2013 and December 2014
Variables Description N = 268
Age, years Median (IQR) 27 (24–31)
Age groups, years 15–24 76 (28.4)
25–34 156 (58.2)
35 and above 36 (13.4)
Educational Level None 5 (1.9)
Completed primary 147 (54.8)
Completed secondary
and above
116 (43.3)
Marital Status Single 60 (22.4)
Married 171 (63.8)
Others (divorced,
widow)
37 (13.8)
Religious affiliation Catholic 59 (22.0)
Presbyterian 88 (32.8)
Baptist 16 (6.0)
Pentecostals 100 (37.3)
Muslim 5 (1.9)
Occupation Unemployed 105 (39.2)
Employed (formal
public sector)
14 (5.2)
Employed (informal
sector) or others
149 (55.6)
HIV status Known HIV positive,
not on ART
34 (12.7)
New HIV diagnosis 234 (87.3)
ART status ART naive 234 (87.3)
Not on ART, but
previously exposed
4 (1.5)
Currently on
Option A
30 (11.2)
Timing of ART initiation After delivery 15 (5.6)
Prior to labour
/delivery
253 (94.4)
CD4 cell count at ART
initiation, cells/μL
Median (IQR) 376 (244–544.8)
CD4 cell count groups > 350 cells/μL 153 (57.1)
≤350 cells/μL 115 (42.9)
WHO stage WHO stage 1 226 (84.3)
WHO stage 2 35 (13.1)
WHO stage 3 7 (2.6)
WHO stage 4 0 (0)
Data are in numbers and percentages [n (%)] or for continuous variables in
median and Interquartile range (IQR)
Table 3 Antiretroviral treatment adherence as assessed by
different measures (pharmacy refill, self-reported questionnaire,
and Visual Analogue Scale) and the composite adherence score
at month 6 and 12 after ART initiation
Adherence variable Adherence
score
Adherence
month 6
Adherence
month 12
N = 217 N = 185
Pharmacy refill High 183 (84.3) 150 (81.1)
Moderate 17 (7.8) 12 (6.5)
Low 17 (7.8) 23 (12.4)
Self-reported questionnaire High 159 (69.1) 143 (77.3)
Moderate 43 (19.8) 31 (16.8)
Low 15 (6.9) 11 (5.9)
Visual Analogue Scale (VAS) High 150 (69.1) 135 (73.0)
Moderate 39 (18.0) 25 (13.5)
Low 28 (12.9) 25 (13.5)
Composite adherence score (CAS) High 128 (59.0) 116 (62.7)
Moderate 68 (31.4) 46 (24.9)
Low 21 (9.6) 23 (12.4)
Data are in numbers and percentages [n (%)]
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occurs more as an instinct, and 22 (12.8%) mentioned
the use of alarm clocks. Among the less frequently cited,
14 (8.1%) declared being reminded by their husbands, 4
(2.3%) relied on a television series and 4 (2.3%) had their
drugs by their bedside. Two additional tables show the
clients responses to these two questions in more details
[see Additional file 1; Tables 1 and 2].
Discussion
Using a composite adherence score (CAS) we deter-
mined adherence in association with viral suppression
and risk factors of poor adherence in a cohort of
HIV-positive pregnant and breastfeeding women who
remained in care at 6 and 12 months after initiating
ART as part of Option B+. The study demonstrated that
of those women who remained in care after Option B+
initiation, 59.0 and 31.4% were either highly or moder-
ately adhering to their treatment as per our CAS tool at
6 month, and 62.7 and 24.9% at month 12, respectively.
The predictive accuracy of the CAS tool was reflected by
virological suppression rates, which were 100% in
women who scored high, 89.5% who scored moderate,
and 52.9% who scored low with the CAS tool at month
12. Low CAS adherence as compared to moderate ad-
herence was significantly associated with virological fail-
ure (OR 7.6, p = 0.005). In our cohort, moderate to high
adherence scores by the CAS tool were sufficient to
reach more than 90% of viral suppression (< 1000 cop-
ies/mL) as defined by the UNAIDS targets, thus 90.8%
of women at 6 months and 87.6% at 12 months were
considered with good adherence to reach durable treat-
ment response. Our adherence levels were comparable
with findings of earlier reports of good adherence with
Option B+ from Eastern Africa [13, 32], but slightly
higher than adherence reported for the same target
group from an Option A study [33]. Adequate adherence
Table 4 Correlation coefficient between each two adherence measures and between each adherence measure and the CAS at 6
and 12 months (Spearman correlation)
Timing of adherence evaluation
6 month 12 month
Adherence Tool Pharmacy refill Self-report VAS CAS Pharmacy refill Self-report VAS CAS
Pharmacy refill 1.00 0.42 0.52 0.62 1.00 0.36 0.66 0.72
Self-report – 1.00 0.53 0.77 – 1.00 0.49 0.71
VAS – – 1.00 0.83 – – 1.00 0.83
Table 5 Association between adherence scores by different adherence tools and virological suppression in pregnant and
breastfeeding women at 12 months after ART initiation
Adherence variable Participants who
received VL
assessments
N = 165
VL≥ 1000 copies/mL
N = 12 (7.3)
VL < 1000 copies/mL
N = 153 (92.7)
aOR (95%CI) P-value
Pharmacy refill
Low adherence 17 (10.3) 6/17 (35.3) 11/17 (64.7) 14.4 (3.8–54.8) 0.0001
Moderate adherence 11 (6.7) 1/11 (9.1) 10/11 (90.9) 2.6 (0.3–24.8) 0.395
High adherence 137 (83.0) 5/137 (3.6) 132/137 (96.4) 1
Self-report
Low adherence 7 (4.2) 4/7 (57.1) 3/7 (42.9) 21.2 (4.0–111.2) 0.0003
Moderate adherence 25 (15.2) 2/25 (8.0) 23/25 (92.0) 1.4 (0.3–6.9) 0.695
High adherence 133 (80.6) 6/133 (4.5) 127/133 (95.5) 1
VAS
Low adherence 18 (10.9) 9/18 (50.0) 9/18 (50.0) 124.0 (14.1–1090.4) < 0.0001
Moderate adherence 22 (13.3) 2/22 (9.1) 20/22 (90.9) 12.4 (1.1–143.0) 0.06
High adherence 125 (75.8) 1/125 (0.8) 124/125 (99.2) 1
CAS
Low adherence 17 (10.3) 8/17 (47.1) 9/17 (52.9) 7.6 (1.8–30.8) 0.005
Moderate adherence 38 (23.0) 4/38 (10.5) 34/38 (89.5) 1
High adherence 110 (66.7) 0 (0.0) 110/110 (100) –
Data are in numbers and percentages [n (%)].abinary logistic regression, OR (crude odd ratio)
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assessment is important to better understand and opti-
mise the success of the Option B+ programme.
A key strength of this study was the use of a CAS to as-
sess adherence in this population. To our knowledge this
is the first study to measure adherence to ART in the con-
text of Option B+ using a CAS. We found a high level of
correlation between all single adherence measures (phar-
macy refill, self-reported adherence, and VAS) and the
CAS which were also all associated with the 12 months
viral suppression indicating the validity of each of the
measures. It has been argued that the use of a CAS to
measure adherence may be cumbersome in routine clin-
ical settings [34]. Our observed close correspondence be-
tween the VAS and the CAS suggests that a single and
less cumbersome tool like the VAS could be more con-
veniently used in clinical settings, and this observation
was also reported in other older studies [30, 31, 35]. Fur-
thermore, in a recent review of adherence and retention
beyond Option B+ the authors’ claimed that the paucity of
literature on adherence in this population was due to the
lack of adherence measure systematically used in routine
care [36]. This thus justifies the importance of a simple
tool like the VAS for routine adherence assessment at the
point of care. Among clients with virologic failure who re-
ported a high adherence, 50% came from self-reported ad-
herence indicating its high vulnerability to social
desirability and recall biases [29]. Despite its mediocre
performance as an adherence assessment tool in predict-
ing virologic failure, we would still argue that self-reported
questionnaires remains useful in providing additional in-
formation necessary to provide adequate adherence sup-
port to clients with adherence challenges.
Viral suppression rates in women who remained in
care at 12 months in our study (92.7%) outreached the
UNAIDS 2020 target [21], suggesting that viral suppres-
sion is achievable both in pregnancy and/or breastfeed-
ing. However, 8.5% of our women had low replicating
viraemia between 40 and 999 copies/mL, and given the
low genetic resistance barrier of non-nucleotide reverse
transcriptase inhibitor containing regimens, close moni-
toring is required to promptly identify treatment failure
and switch clients to a second line therapy.
Risk factors for low adherence to ART were younger
age, low level of education and employment in the infor-
mal sector. Younger age and low level of education had
been reported as predictors of lost to follow-up and
Table 6 Risk factors for low adherence using the composite adherence score (CAS) at 12 months following Option B+ initiation
with adjusted odd ratios (aOR) for 5 health facilities in Kumba health district
Variables Low
adherence
N = 85
Moderate
or high
adherence
N = 162
Bivariate analysisa Multivariate analysisb
OR
(95% CI)
P-value aOR
(95% CI)
P-value
Age (years)
15–24 29 (42.0) 40 (58.0) 2.4 (0.9,5.9) 0.07 3.8 (1.4, 10.6) 0.01
25–34 48 (33.3) 96 (66.7) 1.6 (0.7,3.9) 0.27 1.9 (0.8,4.6) 0.18
35 and above 8 (23.5) 26 (76.5) 1 1
Educational Level
None 1(20.0) 4 (80.0) 0.8 (0.1,7.8) 0.87 1.3 (0.1,15.2) 0.81
Completed primary 59 (44.0) 75 (56.0) 2.6 (1.5,4.6) 0.001 2.7 (1.4,5.2) 0.001
Completed secondary and above 25 (23.1) 83 (76.9) 1 1
Occupation
Unemployed 23 (24.2) 72 (58.8) 1 1
Employed formal sector 5 (38.5) 8 (61.5) 2.0 (0.6,6.6) 0.28 3.9 (1.0,14.8) 0.055
Employed informal sector 57 (41.0) 82 (59.0) 2.2 (1.2,3.9) 0.01 1.9 (1.0,3.6) 0.05
Religious affiliation
Catholic 20 (36.4) 35 (63.6) 1 1
Protestants (Presbyterians/Baptist) 26 (28.3) 66 (71.7) 0.7 (0.3,1.4) 0.31 0.6 (0.3,1.4) 0.24
Pentecostals 39 (41.1) 56 (58.9) 1.2 (0.6,2.4) 0.57 1.1 (0.5,2.3) 0.88
Muslim 0 (0.0) 5 (100.0) – –
CD4 at initiation
< 350 cells/μL 41 (38.7) 65 (61.3) 1.4 (0.8,2.4) 0.22 1.4 (0.8,2.3) 0.23
> 350 cells/μL 44 (31.2) 97 (68.8) 1 1
Data are in numbers and percentages [n (%)],abinary logistic regression, OR (crude odd ratio), aOR (adjusted odd ratio)]. badjusted for age, level of education,
occupation, religious afiliation, WHO staging and CD4 count at ART initiation
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treatment discontinuation [8, 20]. Older women with
more experience and better self-care skills/abilities may
be more responsible towards their health compared to
younger women [20]. Employees in the informal sector
have their own unique work challenges and stresses,
which can adversely affect their ability to concentrate on
health and medication adherence. A South African study
showed that conflict with work commitment and the dif-
ficulty of disclosing ones HIV status to an employer af-
fected ARV adherence in women on Option B+ [37].
Potential strategies to mitigate these challenges include
flexible clinics opening hours like evenings or weekends
when most workers are free and do not need employer’s
permission or a day off just to attend clinic.
Like other studies from sub-Saharan Africa, most par-
ticipants in this study cited forgetfulness, being away
from home and lack of transport to the health facility as
possible reasons for missing doses [32, 38, 39]. Our
study participants also indicated that reminder aids like
cell phones, alarm clocks and reminder from family
members helped improved their adherence. A good pro-
portion of the respondents (36.6%) claimed that medica-
tion taking had become a routine for them so they
needed no reminders. Of these, 88.2% had viral suppres-
sion showing that they had in fact adapted this routinely.
This claim for those not virally suppressed may just
covey their good intentions to continue taking their
medication or methodological problems such as social
desirability concerns. Recent studies have shown that
the use of cell phones short message reminders can
greatly improve adherence [40–42]. The role of family
members like husbands and sisters to remind clients
take their medication could improve adherence [13, 33].
Limitations
The main limitation in this study was that adherence and
virological suppression might had been overestimated as
assessment was limited to women who retained in treat-
ment, and may therefore not be representative of all
HIV-positive women engaged in the Cameroon’s Option B
+ programme. Despite the fact that we prefaced with a
normalising language, the self-reported questionnaires
and VAS may still had been prone to recall and social de-
sirability biases. The small sample size also limited further
analyses. Despite these limitations, our findings had
shown that the VAS and the CAS both reliably predicted
virological response in a clinical context thus could be
used to assess adherence especially in resource limited set-
tings where VL access may be limited. We therefore, be-
lieve that the study findings are useful to inform
implementation of PMTCT Option B+ and to a certain
extent the Test and Treat strategy in Cameroon and other
comparable settings.
Conclusions
During the first year of the Option B+ implementation
in Cameroon we used a novel adherence tool, which ef-
fectively provided an adherence score that correlated
well with viral suppression. However, younger, less edu-
cated and informal sector employed pregnant and
breastfeeding women may need more attention for opti-
mal adherence to help reduce the risk of virological
failure.
Additional file
Additional file 1: Table S1. Reasons for missing ART doses amongst
women on Option B+ in Kumba health district. Table S2. Means of
reminding women to take ART amongst women on Option B+ in Kumba
Health district. During adherence assessment at month 12, women were
asked about reasons why medication doses were missed, and 65.4%
(121) provided one or more reasons. Frequently cited reasons were
forgetfulness 35.5% (43), travel away from home 24.0% (29) and lack of
transport to the clinic 23.1% (28). Stigmatization, being distracted by the
baby, being away for work and being involved in church or other social
activities were less frequently cited. Asking about means which women
used to remind themselves of medications taking, 93.0% (172) provided
one or more responses. The most frequently cited were the use of cell
phone 37.2% (64), many indicated that medication taking had become a
routine in their life so it occurs more as an instinct 36.6% (63), and 18.8%
(22) mentioned the use of alarm clocks. Among the less frequently cited,
7.6% (13) declared being reminded by their husbands, 2.3% (4) relied on a
TV series and 2.3% (4) others had their drugs by their bedside. (PDF 34 kb)
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